• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An ionic liquid loaded magnetically confined polymeric mesoporous adsorbent for extraction of parabens from environmental and cosmetic samples?
  Masrudin Md Yusoff,Muggundha Raoov,Noorfatimah Yahaya,Noorashikin Md Salleh RSC Adv., 2017,7, 35832-35844
• 3. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 4. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 5. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856

Recent Advances in the Study of 7-(3-hydroxypropyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione (CAS: 578697-67-3)

The compound 7-(3-hydroxypropyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione (CAS: 578697-67-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This purine derivative, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, mechanism of action, and potential clinical applications, making it a compound of considerable interest to researchers and industry professionals alike.

One of the key areas of investigation has been the compound's interaction with adenosine receptors, particularly the A_2A and A_2B subtypes. Preliminary in vitro and in vivo studies suggest that 578697-67-3 exhibits high affinity and selectivity for these receptors, which are implicated in a range of physiological processes, including inflammation, immune response, and cardiovascular function. The compound's ability to modulate these receptors has sparked interest in its potential as a therapeutic agent for conditions such as Parkinson's disease, chronic inflammation, and certain types of cancer.

Recent advancements in synthetic chemistry have also facilitated the development of more efficient and scalable routes for the production of 578697-67-3. Researchers have reported improved yields and purity through optimized reaction conditions and novel catalytic systems. These developments are critical for ensuring the compound's availability for further preclinical and clinical studies, as well as for potential large-scale manufacturing.

In addition to its receptor-binding properties, 578697-67-3 has been investigated for its pharmacokinetic and pharmacodynamic profiles. Studies have demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) characteristics, along with a satisfactory safety profile in animal models. These findings underscore the compound's potential as a viable candidate for further drug development.

Looking ahead, ongoing research aims to explore the compound's efficacy in more complex disease models and to identify potential synergies with existing therapies. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications. As the body of evidence grows, 578697-67-3 is poised to become a significant player in the next generation of therapeutic agents targeting adenosine receptor-mediated pathways.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)